Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Extra funding would cut UK breast cancer deaths:

This article was originally published in Clinica

Executive Summary

An increase in funding of £9.7 million ($16 million) for the UK National Health Service breast screening programme could prevent more than 5,000 deaths, a new study has shown. Researchers in the Netherlands and the UK estimate that extending the programme to include women between the ages of 64 and 69 would reduce mortality by 16.4%, preventing 5,311 deaths over a 27-year period. The study, published in the August 8 edition of the British Medical Journal, also estimates that reducing the interval between screenings to two years would reduce the number of deaths by 15.3%.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT083189

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel